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Autoimmune thyroid disease may occasionally associate with unspecific neurological symptoms, which are more commonly
insidious, include cognitive or behavioural symptoms, andmay associate with tremor, myoclonus, or ataxia.We report a 61-year-old
female patient who presented with chronic headache, insidious mood, and cognitive disturbance which evolved in a few months
to dementia associated with exuberant limb myoclonus. Diagnostic workup revealed high anti-thyroid peroxidase antibody titers
and an inflammatory CSF profile, and it was negative for other possible etiologies. Treatment with steroids induced significant
improvement. The diagnosis of encephalopathy associated with autoimmune thyroid disease is still controversial given the fact
that the clinical presentation and diagnostic workup are unspecific, the pathophysiology is still undetermined, and the diagnosis is
mostly of exclusion. No direct correlation is found between anti-thyroid antibody titers and clinical presentation, and it is currently
speculated that other still unrecognized antibodies may be responsible for this clinical entity. It is extremely important to recognize
this entity because it is potentially treatable with immunotherapies. It is also increasingly recognized that clinical improvement with
first-line treatment with steroids may be absent or incomplete, and other immunotherapies as immunosuppressants, intravenous
immunoglobulin, or plasma exchange must be attempted in the clinical suspicion of EEAT.
1. Introduction
Encephalopathy associated with autoimmune thyroid dis-
ease (EAAT) is a rare clinical entity, which presents with
unspecific neurological symptoms. The clinical presentation
is more frequently insidious, with cognitive and behavioural
disturbance that may associate with tremor, myoclonus, or
ataxia. More rarely, clinical onset may be acute as stroke-like
episodes, epilepsy, or psychosis [1–6].
Diagnostic investigation is usually unspecific and there
is no direct correlation between thyroid hormone levels or
anti-thyroid antibody titers and the clinical presentation [1–
3].The current diagnostic criteria are based on the association
of neurological or psychiatric symptoms, presence of anti-
thyroid antibodies, exclusion of other possible causes, and
significant improvement with immunotherapies [7], which
make this entity mostly a diagnosis of exclusion.
We report a 61-year-old female patient who presented
with chronic headache, insidiousmood, and cognitive distur-
bance evolving to rapidly progressive dementia with exuber-
ant limb myoclonus. Diagnostic workup identified high anti-
thyroid antibody titers and excluded other causes, leading to
diagnosis of EAAT. Significant improvement was achieved
with steroid treatment.
With this paper we underline the importance of con-
sidering EAAT when approaching patients with rapidly
progressive neurological or psychiatric symptoms, since it is
a potentially reversible condition with appropriate treatment.
2. Case Report
We report a 61-year-old Caucasian woman who first pre-
sented to our Neurology Emergency Department in March
2012 complaining of severe chronic daily headache. The
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headache was started 9 months before and was described
as bilateral, with pressing-type quality, without associated
symptoms such as nausea, photophobia, or phonophobia,
and did not worsen with recumbency, exercise, or Valsalva
manoeuvres.The patient also presented apathy with progres-
sive loss of interest in life for 18 months and had already
been evaluated by a Psychiatrist who diagnosed depressive
syndrome given that these features immediately followed the
return to her country after 40 years living abroad, leaving
behind her children and grandchildren. However, despite
antidepressive treatment, she presented gradual worsening
and became unable to perform her usual activities of daily
living without supervision (such as cooking, using the tele-
phone, handling money, and taking her medication) and she
spent most days in bed in the last three months. The patient
also complained of upper limb tremorwith left predominance
for the same period.
She had history of arterial hypertension, dyslipidemia,
and hypothyroidism due to Hashimoto’s thyroiditis chron-
ically treated with levothyroxine. There was no history of
recent or chronic infections or toxic exposure. Familial
medical history was unremarkable.
The general physical examination was normal. The neu-
rological examination revealed cognitive impairment with
Mini Mental State Examination of 23 points (3 years of
education). She presented frontal functions impairment with
low verbal fluency, perseveration, impairment of abstract
thinking, and signs of frontal release, namely, glabellar reflex.
Visuospatial impairment was also observed with inability
to copy a drawing or perform the clock-drawing test. An
upper limb rest and postural tremor with left predominance
was identified, without other focal signs in the neurological
examination.
A brain computerized tomography (CT) and blood anal-
ysis were performed in the Emergency Department with
normal results. On discharge a follow-up appointment was
planned for dementia study. In the next weeks, a rapidly
progressive neurological deterioration occurred; the patient
became unable to walk and totally dependent and presented
exuberant myoclonus in the distal upper limbs, so she was
admitted for more investigations.
Extensive blood workup including full blood count,
coagulation study, liver function test, creatinine, erythrocyte
sedimentation rate, c-reactive protein, protein electrophore-
sis, vitamin B12, folic acid, thyroid function, and serologies
(Treponema pallidum, Brucella spp., Borrelia burgdorferi,
Coxiella burnetii, Rickettsia conorii, HIV, and hepatitis B and
C) was normal. Study of systemic autoimmunity, includ-
ing antinuclear antibodies, anti-ds-DNA, anti-SSA, anti-SSB,
anti-RNP, anti-Scl70, anti-Jo1, anti-neutrophil cytoplasmic
antibodies, and anti-thyroid antibodies, revealed only high
titers of anti-thyroid peroxidase antibodies (anti-TPO anti-
bodies) equal to 1008UI/mL (normal<40UI/mL). Onconeu-
ral antibodies (anti-Hu, anti-Ri, anti-Yo, anti-amphiphysin,
anti-Ma2, and anti-CV2) and tumoral markers (Carcinoem-
bryonic Antigen, CA 19.9, CA 125, and CA 15.3) were
negative. Antibodies against neuronal surface antigens (LGI-
1 protein, NMDA AMPA, and GABA-B receptors) were also
negative.
Cerebrospinal fluid (CSF) analysis revealed slightly
increased proteins (72mg/dL) and lymphocytic pleocy-
tosis with 17 cells/mm3. CSF direct microscopy, cultures,
and serologies (Herpes simplex 1 and 2, Cytomegalovirus,
Epstein-Barr virus,Treponema pallidum, Borrelia burgdorferi,
and Brucella spp.) were negative. Oligoclonal bands were
absent and CSF dementia biomarkers (beta-amyloid peptide,
tau protein, and phosphorylated tau protein) were normal.
Electroencephalogram (EEG) revealed rhythmic slow
activity in both temporal regions, with normal background
rhythm and without paroxysmal activity.
Brain Magnetic Resonance Imaging (MRI) was unre-
markable and brain perfusion single-photon emission com-
puted tomography (SPECT) imaging revealed hypoperfusion
in frontal, temporal, and parietal regions with left predomi-
nance (Figure 1).
The rapidly progressive neurological and psychiatric
symptoms presented by the patient were unspecific and it
could be the presentation of several different conditions
including metabolic or toxic encephalopathy, CNS infection,
cerebrovascular disease, CNS tumor, and CNS inflamma-
tory conditions, such as cerebral vasculitis, autoimmune
encephalitis, or paraneoplastic syndromes, or, more remotely,
a rapidly progressive presentation of a degenerative dementia.
The clinical history and diagnostic investigations excluded
most of these causes and given that the only relevant find-
ings were an inflammatory CSF profile and an increased
anti-TPO antibodies titer, encephalopathy associated with
autoimmune thyroid disease was diagnosed and treatment
with intravenous methylprednisolone (1 g/day for 5 days)
was performed. A significant improvement occurred after
five days of therapy with complete resolution of mood and
cognitive disturbance (MMSE = 29) and disappearance of the
myoclonicmovements. EEGwas repeatedwith normal result.
No steroid side effects occurred and, after improvement, the
patient was discharged with oral prednisolone (1mg/kg/day).
One month after discharge, steroid dosage reduction
was attempted, but neurocognitive symptoms and distal
limb myoclonus rapidly returned (anti-TPO antibodies =
217UI/mL). Improvement was promptly seen after pred-
nisolone reincrease to 1mg/kg/day; however, steroid side
effects developed, including Diabetes and Cushing Syn-
drome, so azathioprine was added as a steroid sparing agent.
Although steroid gradual withdrawal was possible after 6
months without symptoms recurrence, the patient developed
toxic hepatitis in relation to azathioprine and the drug
was stopped. Neurological and psychiatric symptoms and
myoclonic movements returned and were rapidly controlled
with low prednisolone dosage (10mg/day) without associated
side effects, and other therapies such as plasma exchange,
intravenous immunoglobulins, or other immunosuppressive
drugs were not necessary. Three years later the patient was
still asymptomatic, although anti-TPO antibody titer remains
elevated (493UI/mL). She is currently on prednisolone
5mg/day as she is reluctant to discontinue for the risk of
recurrence of symptoms.
Figures 2 and 3 represent the evolution in time of
anti-TPO antibody titers and thyroid hormones levels and
their relation with clinical presentation. Although anti-TPO
Case Reports in Medicine 3
Feet to Head Transversal Slice thickness 6.63mm
Right to Left Sagittal Slice thickness 6.63mm
1
1
1Anterior to Posterior Coronal Slice thickness 8.84mm
1211109876
19181716151413
12111098
7
191817161514
13
20
1211109876
1918
1716151413
Change AC
Vol Rendered
3
Figure 1: Brain perfusion SPECT. Reduced 99mTc-HMPAO uptake in parietal, temporal, and frontal lobes. Hypoperfusion is more severe
on the left hemisphere.
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Figure 2: Evolution of anti-thyroid peroxidase antibodies (anti-
TPO antibodies) titers in time and their relationship with clinical
exacerbation.
antibody titer is increased, there is no direct relationship
with clinical presentation, including asymptomatic periods
associated with elevated antibodies.
3. Discussion
Encephalopathy associated with autoimmune thyroid dis-
ease, also called Hashimoto’s encephalopathy or Steroid-
Responsive Encephalopathy associated with Autoimmune
thyroid disease, is a controversial entity as its pathophysi-
ology is not yet well defined and it is usually a diagnosis
of exclusion. It is known to be associated with clinical or
subclinical autoimmune thyroid disease, most commonly
Hashimoto’s thyroiditis, but there are also some reports of
association with Graves Disease, a clinical entity without true
thyroiditis [8–13].
Although autoimmune thyroiditis and the presence of
anti-thyroid antibodies are relatively common in the popula-
tion, with an estimated prevalence of Hashimoto thyroiditis
of 0.3 to 2% [14–16] and detection of anti-thyroid antibodies
in up to 10% healthy population [17–19], encephalopathy
associated with thyroiditis or anti-thyroid antibodies is
very uncommon, with an estimated prevalence of 2.1 per
100.000 habitants [20]. It occurs more commonly in females
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Figure 3: Evolution of thyroid hormone levels in time and their
relationship with clinical exacerbation.
(4 : 1 ratio), and, although there are cases reported from
childhood through the eighth decade of life, the mean age of
onset is in the fourth decade [1, 2].
Since the first description of Hashimoto’s encephalopathy
in 1966 [21], the clinical spectrum has been widened and dif-
ferent possible presentations are now recognized, including
acute-onset presentations as stroke-like episodes, epilepsy,
or psychosis, and a slowly progressive presentation, which
appears to be more common, characterized by cognitive and
behavioral disturbances which may be associate with tremor,
myoclonus, or ataxia [1–4].
The diagnostic criteria of EAAT include the association of
neurological or psychiatric manifestations, high titers of anti-
thyroid antibodies, exclusion of other possible causes with
complementary exams, and a good response to immuno-
suppressive therapy [3, 7]. However, these vague diagnostic
criteria may contribute to masquerade of other autoimmune
encephalopathies instead.
In fact, blood workup is usually normal, except for
the presence of increased anti-thyroid antibodies, more
commonly against thyroid peroxidase (86%), but anti-
thyroglobulin antibodies may be present in some cases (48%)
[1–3]. Despite this association, there is no direct correlation
between antibody titers and the clinical severity, with some
asymptomatic patients having high antibody titers and some
patients with severe encephalopathy having only mildly
increased antibody titers. The absence of direct correlation
between clinical presentation and anti-thyroid antibodies
levels complicates the diagnosis and therefore the evidence of
CNS inflammation, assessed in the cerebrospinal fluid (CSF),
so the exclusion of other causes is essential to the assumption
of this diagnosis.Thyroid hormones levels are also not related
to the course of the disease with themajority of patients being
euthyroid (18–45%) or hypothyroid (clinical in 25–35% and
subclinical in 17–20%) and less commonly hyperthyroidism
(7%) [1–3]. In fact thyroid hormone levels are usually normal
or only mildly abnormal not to explain the psychiatric or
neurological symptoms.
CSF analysis usually reveals mild and nonspecific inflam-
mation that is mild mononuclear pleocytosis or slightly
increased proteins [2, 13]; oligoclonal bands have been
reported [6].
EEG abnormalities are usually present, occurring in 90
to 98% of patients, usually with unspecific findings [22]. The
most common presentations are diffuse background slowing
and frontal intermittent rhythmic delta activity (FIRDA)
[1, 6], but other EEG patterns have been described such as
periodic lateralized epileptiformdischarges (PLEDs) [23] and
temporal epileptiform activity [24, 25].There is usually a cor-
relation between the slowing severity and the encephalopathy
severity [6, 24, 26] and an EEG normalization occurs with
successful treatment, which may also be used to support the
diagnosis [3, 27].
Brain MRI may be normal or, in up to 50% of cases,
present unspecific anomalies, and it is very important to
exclude other etiologies [1, 6]. The abnormalities that may
be seen are cerebral atrophy, or less frequently, focal cortical
abnormalities or unspecific focal or diffuse subcortical white
matter hyperintensities which may be reversible with treat-
ment [1, 3].
SPECT scan is not routinely used, but it was performed
in some previous reports, with unspecific patterns of reduced
perfusion, which can be diffuse or patchy and may involve
multiple different regions [3, 28–30]. Positron emission
tomography (PET) is also unspecific and usually shows
widespread multifocal hypometabolism [31, 32].The findings
in SPECT and PET do not appear to be correlated with the
clinical presentation, EEG, or neuroradiological findings and
usually improve after successful treatment.
The pathogenesis underlying the encephalopathy asso-
ciated with autoimmune thyroid disease is still unknown.
Although anti-thyroid antibodies have no established
pathogenic role, as there is no direct correlation between
antibody titers and clinical severity [1–3], the high prevalence
of coexistence of thyroid autoimmune diseases and other
autoimmune diseases is well described [33, 34]. Therefore,
the presence of anti-thyroid antibodies may be related to an
autoimmune predisposition and the presence of other, still
unrecognized, antibodies responsible for the encephalopathy
may be speculated.
Antibodies against alpha-enolase, an antigen present in
thyroid and also diffusely in the brain, have been described
in some patients [35, 36]; however, their involvement in the
pathogenesis has not been yet documented. The presence
of antibodies against neuronal antigens is also suggested
although it remains to be proven [37].
Given that EAAT is considered an inflammatory con-
dition, the current treatment is based on immunotherapy.
The most commonly used treatment is intravenous methyl-
prednisolone (500–1000 g/day, for 3 to 5 days) followed by
oral prednisone (1-2mg/kg/day), which is gradually tapered
with clinical improvement. Immunosuppressants,more com-
monly azathioprine, may be used as steroid sparing agents
[3].
A prompt response to steroids occurs in most patients,
usually with a favourable prognosis [3]. However, there is
only partial benefit in some patients, no response to steroids
is seen in a few cases, and, even after successful treatment,
some patients may have relapses, usually during treatment
withdrawal [3, 13, 25, 37–40]. However, the absence of
response to steroids should not be regarded as a factor against
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this diagnosis, and other immunotherapies must be tried
in cases of strong clinical suspicion. In cases of suboptimal
or absent response to first-line treatment with steroids,
good results have been reported with immunosuppressants
(methotrexate, azathioprine, and cyclophosphamide), peri-
odic intravenous immunoglobulin [41, 42], and plasma
exchange [25]. More recently [43] a role for levetiracetam in
patients ineligible to steroid treatment has been suggested, as
having, in addition to its antiepileptic effects, a possible anti-
inflammatory effect mediated through interleukin-1 beta and
transforming growth factor beta 1.
In our case, both clinical presentation and response to
treatment are in favour of an autoimmune encephalopathy
and criteria to EAAT are met. However, both the absence
of CSF oligoclonal bands and the correlation between blood
antibodies and clinical exacerbation may favour the hypoth-
esis of an autoimmune encephalopathy due to unknown
antibodies, where anti-thyroid antibodies are just indicative
of autoimmune predisposition.
In conclusion, encephalopathy associated with autoim-
mune thyroid disease is a diagnostic challenge as the clinical
presentation and complementary exams are unspecific and
no diagnostic markers are currently available. This condition
is probably underdiagnosed in our clinical practice and,
therefore, a high clinical suspicion is required.With this clini-
cal case we underline the importance ofmaking the diagnosis
of this entity, since it can be treated with immunotherapy and
patient prognosis can be significantly improved.
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Additional Points
(i) Clinical presentation of EAAT is variable and unspe-
cific.
(ii) Complementary exams results are unspecific and no
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possible causes.
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improves with immunotherapies.
Consent
A signed release from the patient authorizing publication has
been obtained.
Competing Interests
All authors report that they have no conflict of interests.
References
[1] J. Y. Chong, L. P. Rowland, and R. D. Utiger, “Hashimoto
encephalopathy: syndrome or myth?” Archives of Neurology,
vol. 60, no. 2, pp. 164–171, 2003.
[2] F. Ferracci and A. Carnevale, “The neurological disorder associ-
ated with thyroid autoimmunity,” Journal of Neurology, vol. 253,
no. 8, pp. 975–984, 2006.
[3] N. C. P. de Holanda, D. D. de Lima, T. B. Cavalcanti, C. S.
Lucena, and F. Bandeira, “Hashimoto’s encephalopathy: system-
atic review of the literature and an additional case,” Journal of
Neuropsychiatry and Clinical Neurosciences, vol. 23, no. 4, pp.
384–390, 2011.
[4] A. Sa´nchez Contreras, S. A. Rojas, A. Manosalva et al.,
“Hashimoto encephalopathy (autoimmune encephalitis),” Jour-
nal of Clinical Rheumatology, vol. 10, no. 6, pp. 339–343, 2004.
[5] J. Payer, T. Petrovic, L. Lisy, and P. Langer, “Hashimoto
encephalopathy: a rare intricate syndrome,” International Jour-
nal of Endocrinology andMetabolism, vol. 10, no. 2, pp. 506–514,
2012.
[6] I. Kothbauer-Margreiter, M. Sturzenegger, J. Komor, R. Baum-
gartner, and C. W. Hess, “Encephalopathy associated with
Hashimoto thyroiditis: diagnosis and treatment,” Journal of
Neurology, vol. 243, no. 8, pp. 585–593, 1996.
[7] G. Tamagno, G. Federspil, and G. Murialdo, “Clinical and diag-
nostic aspects of encephalopathy associated with autoimmune
thyroid disease (or Hashimoto’s encephalopathy),” Internal and
Emergency Medicine, vol. 1, no. 1, pp. 15–23, 2006.
[8] A. Canto´n, O. de Fa`bregas, M. Tintore´, J. Mesa, A. Codina, and
R. Simo´, “Encephalopathy associated to autoimmune thyroid
disease: a more appropriate term for an underestimated con-
dition?” Journal of the Neurological Sciences, vol. 176, no. 1, pp.
65–69, 2000.
[9] S. W. Seo, B. I. Lee, J. D. Lee et al., “Thyrotoxic autoimmune
encephalopathy: a repeat positron emission tomography study,”
Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, no. 4,
pp. 504–506, 2003.
[10] U. Utku, T. Asil, Y. C¸elik, and D. Tucer, “Reversible MR
angiographic findings in a patient with autoimmune Graves
disease,” American Journal of Neuroradiology, vol. 25, no. 9, pp.
1541–1543, 2004.
[11] M. Dihne´, F. J. Schuier, M. Schuier et al., “Hashimoto
encephalopathy following iodine 131 (131I) radiotherapy of
Graves disease,” Archives of Neurology, vol. 65, no. 2, pp. 282–
293, 2008.
[12] G. Gelosa, J. C. DiFrancesco, L. Tremolizzo et al., “Autoimmune
encephalopathy in Graves’ disease: remission after total thy-
roidectomy,” Journal of Neurology, Neurosurgery and Psychiatry,
vol. 80, no. 6, pp. 698–699, 2009.
[13] G. Tamagno, Y. Celik, R. Simo´ et al., “Encephalopathy associ-
ated with autoimmune thyroid disease in patients with Graves’
disease: clinicalmanifestations, follow-up, and outcomes,”BMC
Neurology, vol. 10, article 27, 2010.
[14] A. Staii, S. Mirocha, K. Todorova-Koteva, S. Glinberg, and J. C.
Jaume, “Hashimoto thyroiditis is more frequent than expected
when diagnosed by cytology which uncovers a pre-clinical
state,”Thyroid Research, vol. 3, no. 1, article 11, 2010.
[15] M. P. J. Vanderpump, W. M. G. Tunbridge, J. M. French et
al., “The incidence of thyroid disorders in the community:
a twenty-year follow-up of the Whickham Survey,” Clinical
Endocrinology, vol. 43, no. 1, pp. 55–68, 1995.
6 Case Reports in Medicine
[16] C.Wang and L.M. Crapo, “The epidemiology of thyroid disease
and implications for screening,” Endocrinology and Metabolism
Clinics of North America, vol. 26, no. 1, pp. 189–218, 1997.
[17] M. Afshari, Z. S. Afshari, and S. U. Schuele, “Pearls & oy-
sters: Hashimoto encephalopathy,”Neurology, vol. 78, no. 22, pp.
e134–e137, 2012.
[18] L. Punzi and C. Betterle, “Chronic autoimmune thyroiditis and
rheumatic manifestations,” Joint Bone Spine, vol. 71, no. 4, pp.
275–283, 2004.
[19] C. P. Mavragani, S. Danielides, E. Zintzaras, P. G. Vla-
choyiannopoulos, and H. M. Moutsopoulos, “Antithyroid anti-
bodies in antiphospholipid syndrome: prevalence and clinical
associations,” Lupus, vol. 18, no. 12, pp. 1096–1099, 2009.
[20] F. Ferracci, G. Bertiato, and G. Moretto, “Hashimoto’s enceph-
alopathy: epidemiologic data and pathogenetic considerations,”
Journal of the Neurological Sciences, vol. 217, no. 2, pp. 165–168,
2004.
[21] L. Brain, E. H. Jellinek, and K. Ball, “Hashimoto’s disease and
encephalopathy,”The Lancet, vol. 2, no. 7462, pp. 512–514, 1966.
[22] R. Henchey, J. Cibula, W. Helveston, J. Malone, and R. L.
Gilmore, “Electroencephalographic findings in Hashimoto’s
encephalopathy,” Neurology, vol. 45, no. 5, pp. 977–981, 1995.
[23] C. P. Doherty, M. Schlossmacher, N. Torres, E. Bromfield,
and M. A. Samuels, “Hashimoto’s encephalopathy mimicking
Creutzfeldt-Jakob disease: brain biopsy findings,” Journal of
Neurology Neurosurgery and Psychiatry, vol. 73, no. 5, pp. 601–
602, 2002.
[24] B. Scha¨uble, P. R. Castillo, B. F. Boeve, and B. F. Westmoreland,
“EEG findings in steroid-responsive encephalopathy associated
with autoimmune thyroiditis,”Clinical Neurophysiology, vol. 114,
no. 1, pp. 32–37, 2003.
[25] T. Nagpal and S. Pande, “Hashimoto’s encephalopathy: response
to plasma exchange,”Neurology India, vol. 52, no. 2, pp. 245–247,
2004.
[26] A. J. Rodriguez, G. A. Jicha, T. D. L. Steeves, E. E. Benarroch,
and B. F.Westmoreland, “EEG changes in a patient with steroid-
responsive encephalopathy associated with antibodies to thy-
roperoxidase (SREAT,Hashimoto’s encephalopathy),” Journal of
Clinical Neurophysiology, vol. 23, no. 4, pp. 371–373, 2006.
[27] M. Mijajlovic, M. Mirkovic, J. Dackovic, J. Zidverc-Trajkovic,
and N. Sternic, “Clinical manifestations, diagnostic criteria and
therapy of Hashimoto’s encephalopathy: report of two cases,”
Journal of the Neurological Sciences, vol. 288, no. 1-2, pp. 194–
196, 2010.
[28] C. M. Forchetti, G. Katsamakis, and D. C. Garron, “Autoim-
mune thyroiditis and a rapidly progressive dementia: global
hypoperfusion on SPECT scanning suggests a possible mech-
anism,” Neurology, vol. 49, no. 2, pp. 623–626, 1997.
[29] A. Bocchetta, G. Tamburini, P. Cavolina, A. Serra, A. Loviselli,
and M. Piga, “Affective psychosis, Hashimoto’s thyroiditis, and
brain perfusion abnormalities: case report,” Clinical Practice
and Epidemiology in Mental Health, vol. 3, article 31, 2007.
[30] F. H. Mahmud, A. N. Lteif, D. L. Renaud, A. M. Reed, and C.
K. Brands, “Steroid-responsive encephalopathy associated with
Hashimoto’s thyroiditis in an adolescent with chronic halluci-
nations and depression: case report and review,” Pediatrics, vol.
112, no. 3, pp. 686–690, 2003.
[31] K.-I. Kaida, K. Takeda, N. Nagata, and K. Kamakura,
“Alzheimer’s disease with asymmetric parietal lobe atrophy: a
case report,” Journal of the Neurological Sciences, vol. 160, no. 1,
pp. 96–99, 1998.
[32] E. Pari, F. Rinaldi, E. Premi et al., “A follow-up 18F-FDG brain
PET study in a case of Hashimoto’s encephalopathy causing
drug-resistant status epilepticus treated with plasmapheresis,”
Journal of Neurology, vol. 261, no. 4, pp. 663–667, 2014.
[33] K. Boelaert, P. R. Newby, M. J. Simmonds et al., “Prevalence
and relative risk of other autoimmune diseases in subjects
with autoimmune thyroid disease,” The American Journal of
Medicine, vol. 123, no. 2, pp. 183.e1–183.e9, 2010.
[34] P. E. Knapp, “Risk of other autoimmune diseases increased in
people with Graves’ disease or Hashimoto’s thyroiditis relative
to the general UK population,” Evidence-Based Medicine, vol.
15, no. 5, pp. 158–159, 2010.
[35] A. Fujii, M. Yoneda, T. Ito et al., “Autoantibodies against the
amino terminal of 𝛼-enolase are a useful diagnostic marker of
Hashimoto’s encephalopathy,” Journal of Neuroimmunology, vol.
162, no. 1-2, pp. 130–136, 2005.
[36] H. Ochi, I. Horiuchi, N. Araki et al., “Proteomic analysis of
human brain identifies 𝛼-enolase as a novel autoantigen in
Hashimoto’s encephalopathy,” FEBS Letters, vol. 528, no. 1–3, pp.
197–202, 2002.
[37] T. Oide, T. Tokuda, M. Yazaki et al., “Anti-neuronal
autoantibody in Hashimoto’s encephalopathy: neuropath-
ological, immunohistochemical, and biochemical analysis of
two patients,” Journal of the Neurological Sciences, vol. 217, no.
1, pp. 7–12, 2004.
[38] P. Castillo, B. Woodruff, R. Caselli et al., “Steroid-responsive
encephalopathy associated with autoimmune thyroiditis,”
Archives of Neurology, vol. 63, no. 2, pp. 197–202, 2006.
[39] J. Lopez-Giovaneli, O. Moreaud, P. Faure, I. Debaty, O. Chabre,
and S. Halimi, “Cortico-responsive encephalopathy associ-
ated with autoimmune thyroiditis (SREAT): about two case
reports characterized by a gap between the diagnosis of
autoimmune thyroiditis and neurological disorders,” Annales
d’Endocrinologie, vol. 68, no. 2-3, pp. 173–176, 2007.
[40] R. Mocellin, D. I. Lubman, J. Lloyd, E. B. Tomlinson, and D.
Velakoulis, “Reversible dementia with psychosis: Hashimoto’s
encephalopathy,” Psychiatry and Clinical Neurosciences, vol. 60,
no. 6, pp. 761–763, 2006.
[41] R. Cornejo, P. Venegas, D. Gon˜i, A. Salas, and C. Romero,
“Successful response to intravenous immunoglobulin as rescue
therapy in a patient with Hashimoto’s encephalopathy,” BMJ
Case Reports, vol. 2010, 2010.
[42] S. Jacob and Y. A. Rajabally, “Hashimoto’s encephalopathy:
steroid resistance and response to intravenous immunoglobu-
lins,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76,
no. 3, pp. 455–456, 2005.
[43] L. C. Wong, J. D. Freeburg, G. D. Montouris, and A. D.
Hohler, “Two patients with Hashimoto’s encephalopathy and
uncontrolled diabetes successfully treated with levetiracetam,”
Journal of the Neurological Sciences, vol. 348, no. 1-2, pp. 251–
252, 2015.
